PR Newswire Clinical TrialsOriginal article
CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings
Data ReadoutpositiveCytoSorbDrugSorb-ATRPositive
AI Analysis
Summary
CytoSorbents announced real-world data showing a 37% relative reduction in severe bleeding with CytoSorb in CABG patients on Ticagrelor, with no serious adverse events reported. The company also updated on recent FDA pre-submission meetings for its DrugSorb-ATR device.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Real-world data demonstrated 37% relative reduction in severe bleeding in CABG patients on Ticagrelor, with significant reductions in 24-hour chest tube drainage and red blood cell transfusions, and no serious device-related adverse events
Importance:6/10
Sentiment:
0.75
real-world datableeding reductionCABGFDA pre-submissiondevice
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 2, 2026 11:28 AM